Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W G Nelson

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Der Urologe. Ausg. A|July 25, 2008
[CpG island hypermethylation of the DNA. Perspectives of a molecular biomarker for prostate cancer]P J Bastian, J Ellinger, A von Rücker, et al.
The Journal of Investigative Dermatology|July 1, 1983
Keratin classes: molecular markers for different types of epithelial differentiationT T Sun, R Eichner, W G Nelson, et al.
The Prostate|September 11, 2001
GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissueJ K Parsons, C P Nelson, W R Gage, et al.
Andrology|October 2, 2014
Association of serum inorganic phosphate with sex steroid hormones and vitamin D in a nationally representative sample of menW Wulaningsih, M Van Hemelrijck, K Michaelsson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1997
Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiationT L DeWeese, J C Walsh, L E Dillehay, et al.
Journal of the National Cancer Institute|February 15, 1995
Molecular characterization of defective antigen processing in human prostate cancerM G Sanda, N P Restifo, J C Walsh, et al.
The Journal of Experimental Medicine|June 13, 1998
CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cellsA J Adler, D W Marsh, G S Yochum, et al.
International Journal of Oncology|November 18, 2000
Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivityG L David-Beabes, M J Overman, J A Petrofski, et al.
International Journal of Oncology|February 10, 1998
Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccinesA Nigam, R F Yacavone, M L Zahurak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Methylation of the neutral endopeptidase gene promoter in human prostate cancersB A Usmani, R Shen, M Janeczko, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Der Urologe. Ausg. A|July 25, 2008
[CpG island hypermethylation of the DNA. Perspectives of a molecular biomarker for prostate cancer]P J Bastian, J Ellinger, A von Rücker, et al.
The Journal of Investigative Dermatology|July 1, 1983
Keratin classes: molecular markers for different types of epithelial differentiationT T Sun, R Eichner, W G Nelson, et al.
The Prostate|September 11, 2001
GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissueJ K Parsons, C P Nelson, W R Gage, et al.
Andrology|October 2, 2014
Association of serum inorganic phosphate with sex steroid hormones and vitamin D in a nationally representative sample of menW Wulaningsih, M Van Hemelrijck, K Michaelsson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1997
Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiationT L DeWeese, J C Walsh, L E Dillehay, et al.
Journal of the National Cancer Institute|February 15, 1995
Molecular characterization of defective antigen processing in human prostate cancerM G Sanda, N P Restifo, J C Walsh, et al.
The Journal of Experimental Medicine|June 13, 1998
CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cellsA J Adler, D W Marsh, G S Yochum, et al.
International Journal of Oncology|November 18, 2000
Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivityG L David-Beabes, M J Overman, J A Petrofski, et al.
International Journal of Oncology|February 10, 1998
Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccinesA Nigam, R F Yacavone, M L Zahurak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
Methylation of the neutral endopeptidase gene promoter in human prostate cancersB A Usmani, R Shen, M Janeczko, et al.
Pageof 8